259:
249:
In 2018, an
Independent Data Monitoring Committee found that in the TAHOE phase III trial, Rova-T shortened survival of lung cancer patients compared to SOC chemotherapy topotecan, prompting termination of trial enrollment. Another phase III trial (MERU) demonstrated no survival benefit over placebo.
516:
for "A Study of
Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) " at
73:
601:
468:
421:
472:
1606:
34:
1010:
529:
1586:
327:
1542:
1211:
250:
A phase II trial using the drug as a third-line treatment for relapsed or refractory lung cancer showed objective response rate at just 16%.
1431:
594:
486:
1591:
1068:
995:
900:
1596:
925:
587:
910:
1015:
874:
130:
1559:
554:
238:
653:
1118:
569:
1547:
1514:
1455:
1321:
945:
422:"AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program | AbbVie News Center"
218:
1485:
1475:
1445:
1236:
1181:
1108:
1098:
975:
234:
1601:
1460:
1449:
1411:
1301:
1286:
1216:
1196:
1191:
970:
724:
306:
266:
1311:
1171:
940:
905:
1426:
1396:
1391:
1376:
1206:
1053:
1005:
965:
610:
282:
94:
44:
27:
664:
555:"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 75"
1148:
699:
659:
517:
281:
structure that can be cleaved by an enzyme to detach the anti-cancer agent from the antibody, a
226:
1035:
854:
462:
385:
328:"Statement On A Nonproprietary Name Adopted By The USAN Council: USAN (de-144) Rovalpituzumab"
270:
103:
375:
367:
175:
297:
backbone, drawn blue. Each rovalpituzumab molecule has an average of two such attachments.
139:
20:
1553:
1519:
1186:
380:
355:
1580:
1401:
1256:
809:
644:
1416:
1381:
1366:
1361:
1356:
1351:
1326:
1281:
1276:
1271:
1266:
1251:
1138:
1113:
1093:
955:
920:
859:
839:
649:
634:
579:
201:
512:
447:
1524:
1498:
1493:
1465:
1441:
1436:
1371:
1346:
1336:
1306:
1296:
1261:
1246:
1231:
1221:
1201:
1176:
1161:
1133:
1083:
1078:
1073:
1058:
1048:
1025:
1020:
990:
935:
879:
869:
844:
834:
829:
824:
799:
774:
764:
759:
754:
744:
729:
714:
709:
694:
689:
679:
674:
669:
639:
258:
1470:
1421:
1386:
1316:
1291:
1241:
1226:
1166:
1156:
1128:
1103:
1043:
985:
980:
915:
895:
849:
819:
814:
804:
794:
789:
779:
769:
739:
734:
704:
684:
371:
114:
403:
1341:
1331:
1123:
1088:
1063:
1000:
960:
950:
930:
864:
784:
749:
719:
530:"AbbVie ditches plans for accelerated Rova-T review after weak phase 2 data"
286:
49:
389:
354:
Lashari BH, Vallatharasu Y, Kolandra L, Hamid M, Uprety D (December 2018).
619:
356:"Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate"
290:
294:
278:
56:
274:
230:
265:
Chemical structure of "tesirine" (drawn in black). It consists of a
159:
487:"It's official—AbbVie dumps Rova-T after another lung cancer fail"
257:
222:
150:
61:
583:
237:, but development was terminated after unsuccessful
1507:
1484:
1147:
1034:
888:
627:
618:
174:
169:
149:
129:
113:
93:
88:
72:
67:
55:
43:
33:
26:
273:(top), which is the actual anti-cancer agent, a
225:on tumor cells. It was originally developed by
102:
595:
8:
467:: CS1 maint: multiple names: authors list (
19:
624:
602:
588:
580:
471:) CS1 maint: numeric names: authors list (
379:
138:
448:"Rovalpituzumab tesirine - AdisInsight"
319:
460:
446:Alternative Names: Rova-T; SC16LD6.5.
18:
293:in the antibody's (rovalpituzumab's)
7:
16:Experimental antibody-drug conjugate
158:
404:"Rova-T (Rovalpituzumab tesirine)"
14:
1607:Monoclonal antibodies for tumors
1587:Drugs not assigned an ATC code
289:linker which is attached to a
1:
233:. It was tested for use in
1623:
450:. Adisinsight.springer.com
309:, with a similar cytotoxin
170:Chemical and physical data
1592:Experimental cancer drugs
1537:
1119:Mirvetuximab soravtansine
570:World Health Organization
372:10.1007/s40268-018-0247-7
1597:Antibody-drug conjugates
1515:Depatuxizumab mafodotin
1456:Tucotuzumab celmoleukin
1407:Rovalpituzumab tesirine
1322:Lorvotuzumab mertansine
1212:Clivatuzumab tetraxetan
335:Searchusan.ama-assn.org
219:antibody-drug conjugate
211:Rovalpituzumab tesirine
21:Rovalpituzumab tesirine
1476:Vorsetuzumab mafodotin
1432:Tacatuzumab tetraxetan
1237:Denintuzumab mafodotin
1182:Bivatuzumab mertansine
1109:Loncastuximab tesirine
1099:Indatuximab ravtansine
976:Naptumomab estafenatox
510:Clinical trial number
262:
235:small-cell lung cancer
221:targeting the protein
1461:Vandortuzumab vedotin
1412:Sacituzumab govitecan
1302:Inotuzumab ozogamicin
1287:Gemtuzumab ozogamicin
1217:Cofetuzumab pelidotin
1197:Cantuzumab ravtansine
1192:Cantuzumab mertansine
1011:Nofetumomab merpentan
971:Moxetumomab pasudotox
725:Glembatumumab vedotin
611:Monoclonal antibodies
307:Vadastuximab talirine
267:pyrrolobenzodiazepine
261:
229:and was purchased by
217:) is an experimental
1508:Chimeric + humanized
1312:Lifastuzumab vedotin
1172:Belantamab mafodotin
941:Ibritumomab tiuxetan
906:Anatumomab mafenatox
562:WHO Drug Information
1427:Sofituzumab vedotin
1397:Polatuzumab vedotin
1392:Pinatuzumab vedotin
1377:Oportuzumab monatox
1207:Citatuzumab bogatox
1069:Derlotuximab biotin
1054:Brentuximab vedotin
1006:Taplitumomab paptox
996:Satumomab pendetide
966:Nacolomab tafenatox
901:Altumomab pentetate
283:polyethylene glycol
28:Monoclonal antibody
23:
1564:Never to phase III
926:Capromab pendetide
700:Enfortumab vedotin
518:ClinicalTrials.gov
263:
254:Chemical structure
1574:
1573:
1533:
1532:
855:Tisotumab vedotin
208:
207:
1614:
1486:Rat/mouse hybrid
625:
604:
597:
590:
581:
574:
573:
559:
551:
545:
544:
542:
540:
526:
520:
508:
502:
501:
499:
497:
483:
477:
476:
466:
458:
456:
455:
443:
437:
436:
434:
432:
418:
412:
411:
400:
394:
393:
383:
360:Drugs in R&D
351:
345:
344:
342:
341:
332:
324:
162:
142:
106:
24:
22:
1622:
1621:
1617:
1616:
1615:
1613:
1612:
1611:
1577:
1576:
1575:
1570:
1569:
1554:Clinical trials
1529:
1503:
1480:
1143:
1030:
884:
614:
608:
578:
577:
557:
553:
552:
548:
538:
536:
528:
527:
523:
509:
505:
495:
493:
485:
484:
480:
459:
453:
451:
445:
444:
440:
430:
428:
426:news.abbvie.com
420:
419:
415:
402:
401:
397:
353:
352:
348:
339:
337:
330:
326:
325:
321:
316:
303:
256:
247:
239:phase III trial
199:
195:
191:
187:
183:
165:
145:
125:
109:
84:
17:
12:
11:
5:
1620:
1618:
1610:
1609:
1604:
1599:
1594:
1589:
1579:
1578:
1572:
1571:
1568:
1567:
1566:
1565:
1562:
1551:
1545:
1539:
1538:
1535:
1534:
1531:
1530:
1528:
1527:
1522:
1520:Duvortuxizumab
1517:
1511:
1509:
1505:
1504:
1502:
1501:
1496:
1490:
1488:
1482:
1481:
1479:
1478:
1473:
1468:
1463:
1458:
1453:
1439:
1434:
1429:
1424:
1419:
1414:
1409:
1404:
1399:
1394:
1389:
1384:
1379:
1374:
1369:
1364:
1359:
1354:
1349:
1344:
1339:
1334:
1329:
1324:
1319:
1314:
1309:
1304:
1299:
1294:
1289:
1284:
1279:
1274:
1269:
1264:
1259:
1254:
1249:
1244:
1239:
1234:
1229:
1224:
1219:
1214:
1209:
1204:
1199:
1194:
1189:
1187:Brontictuzumab
1184:
1179:
1174:
1169:
1164:
1159:
1153:
1151:
1145:
1144:
1142:
1141:
1136:
1131:
1126:
1121:
1116:
1111:
1106:
1101:
1096:
1091:
1086:
1081:
1076:
1071:
1066:
1061:
1056:
1051:
1046:
1040:
1038:
1032:
1031:
1029:
1028:
1023:
1018:
1013:
1008:
1003:
998:
993:
988:
983:
978:
973:
968:
963:
958:
953:
948:
943:
938:
933:
928:
923:
918:
913:
908:
903:
898:
892:
890:
886:
885:
883:
882:
877:
872:
867:
862:
857:
852:
847:
842:
837:
832:
827:
822:
817:
812:
807:
802:
797:
792:
787:
782:
777:
772:
767:
762:
757:
752:
747:
742:
737:
732:
727:
722:
717:
712:
707:
702:
697:
692:
687:
682:
677:
672:
667:
662:
657:
654:+hyaluronidase
647:
642:
637:
631:
629:
622:
616:
615:
609:
607:
606:
599:
592:
584:
576:
575:
546:
521:
503:
478:
438:
413:
395:
366:(4): 255–258.
346:
318:
317:
315:
312:
311:
310:
302:
299:
285:spacer, and a
255:
252:
246:
243:
206:
205:
197:
193:
189:
185:
181:
178:
172:
171:
167:
166:
164:
163:
155:
153:
147:
146:
144:
143:
135:
133:
127:
126:
124:
123:
119:
117:
111:
110:
108:
107:
99:
97:
91:
90:
86:
85:
83:
82:
78:
76:
70:
69:
65:
64:
59:
53:
52:
47:
41:
40:
39:Whole antibody
37:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1619:
1608:
1605:
1603:
1600:
1598:
1595:
1593:
1590:
1588:
1585:
1584:
1582:
1563:
1561:
1558:
1557:
1555:
1552:
1549:
1546:
1544:
1541:
1540:
1536:
1526:
1523:
1521:
1518:
1516:
1513:
1512:
1510:
1506:
1500:
1497:
1495:
1492:
1491:
1489:
1487:
1483:
1477:
1474:
1472:
1469:
1467:
1464:
1462:
1459:
1457:
1454:
1451:
1447:
1443:
1440:
1438:
1435:
1433:
1430:
1428:
1425:
1423:
1420:
1418:
1415:
1413:
1410:
1408:
1405:
1403:
1402:Rosmantuzumab
1400:
1398:
1395:
1393:
1390:
1388:
1385:
1383:
1380:
1378:
1375:
1373:
1370:
1368:
1365:
1363:
1360:
1358:
1355:
1353:
1350:
1348:
1345:
1343:
1340:
1338:
1335:
1333:
1330:
1328:
1325:
1323:
1320:
1318:
1315:
1313:
1310:
1308:
1305:
1303:
1300:
1298:
1295:
1293:
1290:
1288:
1285:
1283:
1280:
1278:
1275:
1273:
1270:
1268:
1265:
1263:
1260:
1258:
1257:Enoblituzumab
1255:
1253:
1250:
1248:
1245:
1243:
1240:
1238:
1235:
1233:
1230:
1228:
1225:
1223:
1220:
1218:
1215:
1213:
1210:
1208:
1205:
1203:
1200:
1198:
1195:
1193:
1190:
1188:
1185:
1183:
1180:
1178:
1175:
1173:
1170:
1168:
1165:
1163:
1160:
1158:
1155:
1154:
1152:
1150:
1146:
1140:
1137:
1135:
1132:
1130:
1127:
1125:
1122:
1120:
1117:
1115:
1112:
1110:
1107:
1105:
1102:
1100:
1097:
1095:
1092:
1090:
1087:
1085:
1082:
1080:
1077:
1075:
1072:
1070:
1067:
1065:
1062:
1060:
1057:
1055:
1052:
1050:
1047:
1045:
1042:
1041:
1039:
1037:
1033:
1027:
1024:
1022:
1019:
1017:
1014:
1012:
1009:
1007:
1004:
1002:
999:
997:
994:
992:
989:
987:
984:
982:
979:
977:
974:
972:
969:
967:
964:
962:
959:
957:
954:
952:
949:
947:
944:
942:
939:
937:
934:
932:
929:
927:
924:
922:
919:
917:
914:
912:
909:
907:
904:
902:
899:
897:
894:
893:
891:
887:
881:
878:
876:
873:
871:
868:
866:
863:
861:
858:
856:
853:
851:
848:
846:
843:
841:
838:
836:
833:
831:
828:
826:
823:
821:
818:
816:
813:
811:
810:Pembrolizumab
808:
806:
803:
801:
798:
796:
793:
791:
788:
786:
783:
781:
778:
776:
773:
771:
768:
766:
763:
761:
758:
756:
753:
751:
748:
746:
743:
741:
738:
736:
733:
731:
728:
726:
723:
721:
718:
716:
713:
711:
708:
706:
703:
701:
698:
696:
693:
691:
688:
686:
683:
681:
678:
676:
673:
671:
668:
666:
663:
661:
658:
655:
651:
648:
646:
645:Ascrinvacumab
643:
641:
638:
636:
633:
632:
630:
626:
623:
621:
617:
612:
605:
600:
598:
593:
591:
586:
585:
582:
571:
567:
563:
556:
550:
547:
535:
534:FierceBiotech
531:
525:
522:
519:
515:
514:
507:
504:
492:
491:FierceBiotech
488:
482:
479:
474:
470:
464:
449:
442:
439:
427:
423:
417:
414:
409:
405:
399:
396:
391:
387:
382:
377:
373:
369:
365:
361:
357:
350:
347:
336:
329:
323:
320:
313:
308:
305:
304:
300:
298:
296:
292:
288:
284:
280:
276:
272:
268:
260:
253:
251:
244:
242:
240:
236:
232:
228:
224:
220:
216:
212:
203:
179:
177:
173:
168:
161:
157:
156:
154:
152:
148:
141:
137:
136:
134:
132:
128:
121:
120:
118:
116:
112:
105:
101:
100:
98:
96:
92:
87:
80:
79:
77:
75:
71:
68:Clinical data
66:
63:
60:
58:
54:
51:
48:
46:
42:
38:
36:
32:
29:
25:
1602:Orphan drugs
1417:Sibrotuzumab
1406:
1382:Parsatuzumab
1367:Otlertuzumab
1362:Odronextamab
1357:Ocaratuzumab
1352:Obinutuzumab
1327:Lumretuzumab
1282:Flotetuzumab
1277:Ficlatuzumab
1272:Farletuzumab
1267:Etaracizumab
1252:Emibetuzumab
1139:Zolbetuximab
1114:Margetuximab
1094:Girentuximab
956:Minretumomab
921:Blinatumomab
860:Teprotumumab
840:Seribantumab
665:Botensilimab
650:Atezolizumab
635:Adecatumumab
572:: 151. 2016.
565:
561:
549:
537:. Retrieved
533:
524:
511:
506:
494:. Retrieved
490:
481:
452:. Retrieved
441:
429:. Retrieved
425:
416:
407:
398:
363:
359:
349:
338:. Retrieved
334:
322:
264:
248:
214:
210:
209:
202:glycosylated
104:1613313-09-9
1550:from market
1525:Ontuxizumab
1499:Ertumaxomab
1494:Catumaxomab
1466:Vanucizumab
1446:+deruxtecan
1442:Trastuzumab
1437:Tigatuzumab
1372:Onartuzumab
1347:Nimotuzumab
1337:Milatuzumab
1307:Labetuzumab
1297:Imgatuzumab
1262:Epcoritamab
1247:Emactuzumab
1232:Dalotuzumab
1222:Dacetuzumab
1202:Cirmtuzumab
1177:Bevacizumab
1162:Alemtuzumab
1134:Ublituximab
1084:Ensituximab
1079:Ecromeximab
1074:Dinutuximab
1059:Carotuximab
1049:Bavituximab
1026:Tositumomab
1021:Tenatumomab
991:Racotumomab
936:Edrecolomab
911:Arcitumomab
880:Zalutumumab
870:Vantictumab
845:Sugemalimab
835:Robatumumab
830:Rilotumumab
825:Ramucirumab
800:Panitumumab
775:Necitumumab
765:Mapatumumab
760:Lucatumumab
755:Lexatumumab
745:Istiratumab
730:Intetumumab
715:Flanvotumab
710:Figitumumab
695:Dusigitumab
690:Duligotumab
680:Daratumumab
675:Conatumumab
670:Cixutumumab
660:Balstilimab
640:Amivantamab
513:NCT03033511
245:Development
89:Identifiers
1581:Categories
1471:Veltuzumab
1450:+emtansine
1422:Simtuzumab
1387:Pertuzumab
1317:Lintuzumab
1292:Glofitamab
1242:Elotuzumab
1227:Demcizumab
1167:Axatilimab
1157:Abituzumab
1129:Siltuximab
1104:Isatuximab
1044:Amatuximab
1016:Pintumomab
986:Pemtumomab
981:Oregovomab
916:Bectumomab
896:Abagovomab
850:Tarextumab
820:Radretumab
815:Pritumumab
805:Patritumab
795:Olaratumab
790:Ofatumumab
780:Nesvacumab
770:Narnatumab
740:Iratumumab
735:Ipilimumab
705:Enoticumab
685:Drozitumab
613:for tumors
454:2017-05-22
408:BioCentury
340:2017-05-23
314:References
227:Stemcentrx
140:P256HB60FF
115:ChemSpider
95:CAS Number
1560:Phase III
1548:Withdrawn
1342:Naxitamab
1332:Matuzumab
1149:Humanized
1124:Rituximab
1089:Futuximab
1064:Cetuximab
1001:Solitomab
961:Mitumomab
951:Lilotomab
931:Detumomab
875:Votumumab
865:Tovetumab
785:Nivolumab
750:Icrucumab
720:Ganitumab
539:29 August
496:29 August
431:29 August
287:maleimide
50:Humanized
1036:Chimeric
946:Igovomab
463:cite web
390:30232719
301:See also
291:cysteine
74:ATC code
381:6277321
295:peptide
176:Formula
1543:WHO-EM
388:
378:
231:AbbVie
215:Rova-T
160:D10981
57:Target
45:Source
889:Mouse
628:Human
620:Tumor
568:(1).
558:(PDF)
331:(PDF)
271:dimer
269:type
200:(non-
541:2019
498:2019
473:link
469:link
433:2019
386:PMID
223:DLL3
194:2028
190:1698
186:9894
182:6416
151:KEGG
131:UNII
122:none
81:None
62:DLL3
35:Type
376:PMC
368:doi
279:Ala
275:Val
1583::
1556::
1448:/
566:30
564:.
560:.
532:.
489:.
465:}}
461:{{
424:.
406:.
384:.
374:.
364:18
362:.
358:.
333:.
241:.
198:46
1452:)
1444:(
656:)
652:(
603:e
596:t
589:v
543:.
500:.
475:)
457:.
435:.
410:.
392:.
370::
343:.
277:–
213:(
204:)
196:S
192:O
188:N
184:H
180:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
